BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34213557)

  • 1. Association of the Extension for Community Healthcare Outcomes Project With Use of Direct-Acting Antiviral Treatment Among US Adults With Hepatitis C.
    Tran L; Feldman R; Riley T; Jung J
    JAMA Netw Open; 2021 Jul; 4(7):e2115523. PubMed ID: 34213557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Direct-Acting Antiviral Treatment With Mortality Among Medicare Beneficiaries With Hepatitis C.
    Kalidindi Y; Jung J; Feldman R; Riley T
    JAMA Netw Open; 2020 Jul; 3(7):e2011055. PubMed ID: 32692371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can Telementoring Reduce Urban-Rural Disparities in Utilization of Direct-Acting Antiviral Agents?
    Du P; Wang X; Kong L; Jung J
    Telemed J E Health; 2021 May; 27(5):488-494. PubMed ID: 32882154
    [No Abstract]   [Full Text] [Related]  

  • 4. Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population.
    Marcus JL; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Lam JO; Pauly MP; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ
    Public Health Rep; 2018; 133(4):452-460. PubMed ID: 29750893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial/Ethnic and Socioeconomic Disparities in Use of Direct-Acting Antivirals Among Medicare Beneficiaries with Chronic Hepatitis C, 2014-2016.
    Jung J; Du P; Feldman R; Kong L; Riley T
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1236-1242. PubMed ID: 31663464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States.
    Nguyen VH; Kam L; Yeo YH; Huang DQ; Henry L; Cheung R; Nguyen MH
    JAMA Netw Open; 2022 Dec; 5(12):e2245424. PubMed ID: 36477481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment.
    Haque LY; Fiellin DA; Tate JP; Esserman D; Bhattacharya D; Butt AA; Crystal S; Edelman EJ; Gordon AJ; Lim JK; Tetrault JM; Williams EC; Bryant K; Cartwright EJ; Rentsch CT; Justice AC; Lo Re V; McGinnis KA
    JAMA Netw Open; 2022 Dec; 5(12):e2246604. PubMed ID: 36515952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Direct-Acting Antiviral Agents and Survival Among Medicare Beneficiaries with Dementia and Chronic Hepatitis C.
    Tran L; Jung J; Carlin C; Lee S; Zhao C; Feldman R
    J Alzheimers Dis; 2021; 79(1):71-83. PubMed ID: 33216031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare Beneficiaries.
    Jung J; Feldman R; Kalidindi Y; Riley T
    JAMA Netw Open; 2020 Jun; 3(6):e208081. PubMed ID: 32602909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.
    Jiang X; Vouri SM; Diaby V; Lo-Ciganic W; Parker R; Park H
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1388-1402. PubMed ID: 34595949
    [No Abstract]   [Full Text] [Related]  

  • 11. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.
    Singal AG; Rich NE; Mehta N; Branch AD; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Ioannou GN; Huang A; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Kagan S; Gopal P; Wong R; Parikh ND; Murphy CC
    Gastroenterology; 2019 Nov; 157(5):1253-1263.e2. PubMed ID: 31374215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system.
    Lam JO; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ; Marcus JL
    Int J STD AIDS; 2019 Jun; 30(7):689-695. PubMed ID: 31046611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.
    Zhang M; O'Keefe D; Craig J; Samley K; Bunreth V; Jolivet P; Balkan S; Marquardt T; Dousset JP; Le Paih M
    Lancet Gastroenterol Hepatol; 2021 May; 6(5):371-380. PubMed ID: 33743883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C Treatment Initiation Among US Medicaid Enrollees.
    Kapadia SN; Zhang H; Gonzalez CJ; Sen B; Franco R; Hutchings K; Wethington E; Talal A; Lloyd A; Dharia A; Wells M; Bao Y; Shapiro MF
    JAMA Netw Open; 2023 Aug; 6(8):e2327326. PubMed ID: 37540513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct Acting Antivirals Improve HCV Treatment Initiation and Adherence Among Underserved African Americans.
    Beck KR; Kim NJ; Khalili M
    Ann Hepatol; 2018; 17(3):413-418. PubMed ID: 29735789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disparities in Access to Hepatitis C Treatment Among Arizona Medicaid Beneficiaries With Chronic Hepatitis C.
    Jiang X; Song HJ; Chang CY; Wilson D; Guo J; Lo-Ciganic WH; Park H
    Med Care; 2023 Feb; 61(2):81-86. PubMed ID: 36453625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C.
    McGlynn EA; Adams JL; Kramer J; Sahota AK; Silverberg MJ; Shenkman E; Nelson DR
    JAMA Netw Open; 2019 Jun; 2(6):e194765. PubMed ID: 31173117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.
    Singer AW; Reddy KR; Telep LE; Osinusi AO; Brainard DM; Buti M; Chokkalingam AP
    Aliment Pharmacol Ther; 2018 May; 47(9):1278-1287. PubMed ID: 29516535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct-acting antiviral therapy for hepatitis C: attitudes regarding future use.
    Gaglio PJ; Moss N; McGaw C; Reinus J
    Dig Dis Sci; 2011 May; 56(5):1509-15. PubMed ID: 21336604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus: The Veteran Birth Cohort.
    Njei B; Esserman D; Krishnan S; Ohl M; Tate JP; Hauser RG; Taddei T; Lim J; Justice AC
    Med Care; 2019 Apr; 57(4):279-285. PubMed ID: 30807449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.